Ruxotor Cream
Ruxotor is a generic version of OPZELURA (1.5% ruxolitinib cream) which is a JAK inhibitor indicated for short-term or occasional treatment of mild to moderate eczema and nonsegmental vitiligo patients.
Ruxotor inhibits IFN-γ mediated JAK-STAT signaling, a key driver of depigmentation in vitiligo.
Mild to Moderate Eczema (Atopic Dermatitis)
Atopic dermatitis (AD) is a chronic skin disease marked by itch, inflammation, and skin barrier dysfunction.
Dysregulation of inflammatory cytokines (IL-4, IL-13, IL-31, and TSLP) is believed to be involved in AD pathogenesis. These cytokines signal through the JAK-STAT pathway and are thought to perpetuate the cycle of itch and inflammation in AD.
MOA of Ruxotor Against AD
JAKs are intracellular signaling enzymes that act downstream of key cytokines (IL-4, IL-13, IL-31, and TSLP) and therefore are believed to play a key role in AD itch and inflammation. Especially IL-31 is a key cytokine believed to trigger itch. Ruxotor binds to the JAK enzyme, inhibiting both JAK and STAT activation. As a result, inflammatory mediators are interrupted.
Through topical JAK inhibition, Ruxotor targets the signaling of key cytokines believed to be a source of itch and inflammation.
How to Use Ruxotor in Atopic Dermatitis
- Patients should apply a thin layer 2x a day directly to affected skin areas —up to 20% BSA.
- Patients should not use more than one 60 gram tube per week
- Patients should use Ruxotor until signs and symptoms resolve
- For topical use only. Not for ophthalmic, oral, or intravaginal use.
- If signs and symptoms do not improve within 8 weeks, patients should be re-examined.